NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Forecast, Price & News

$26.13

-0.47 (-1.77%)

(As of 01:20 PM ET)

Compare

Today's Range: $25.93
▼
$26.71
50-Day Range: $21.38
▼
$27.12
52-Week Range: $16.75
▼
$34.76

Volume: 76,326 shs
Average Volume: 493,851 shs
Market Capitalization: $1.45 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.00

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 40.8% Upside
$37.00 Price Target
Short Interest: Bearish
10.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.54
Upright™ Environmental Score
News Sentiment: 0.04
Based on 4 Articles This Week
Insider Trading: Selling Shares
$1.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.16) to ($5.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

640th out of 986 stocks

Pharmaceutical Preparations Industry

305th out of 481 stocks

3.4

Analyst's Opinion

Consensus Rating
Agios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.00, Agios Pharmaceuticals has a forecasted upside of 40.8% from its current price of $26.27.
Amount of Analyst Coverage
Agios Pharmaceuticals has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
10.86% of the float of Agios Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Agios Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Agios Pharmaceuticals has recently increased by 1.58%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Agios Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Agios Pharmaceuticals does not have a long track record of dividend growth.

4.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agios Pharmaceuticals has received a 79.20% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agios Pharmaceuticals is -0.54.

1.7

News and Social Media Coverage

News Sentiment
Agios Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.
MarketBeat Follows
Only 2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,266,695.00 in company stock.
Percentage Held by Insiders
Only 4.24% of the stock of Agios Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.16) to ($5.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agios Pharmaceuticals is -6.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agios Pharmaceuticals is -6.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Agios Pharmaceuticals has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

June 9, 2023 | americanbankingnews.com

Financial Analysis: AbbVie (NYSE:ABBV) & Agios Pharmaceuticals (NASDAQ:AGIO)

June 5, 2023 | finance.yahoo.com

ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer

June 9, 2023 | Edge On The Street (Ad)

All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle

More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...

June 5, 2023 | finance.yahoo.com

Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023

May 30, 2023 | finance.yahoo.com

Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions

May 25, 2023 | finance.yahoo.com

Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?

May 25, 2023 | finance.yahoo.com

Agios Appoints Catherine Owen to Board of Directors

May 24, 2023 | msn.com

Agios Pharmaceuticals: Good Execution, A Good Deal Of Cash, Some Hurdles

June 9, 2023 | Edge On The Street (Ad)

All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle

May 19, 2023 | americanbankingnews.com

Agios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated by Analysts at StockNews.com

May 17, 2023 | americanbankingnews.com

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 6.3% in April

May 11, 2023 | finance.yahoo.com

Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress

May 10, 2023 | marketwatch.com

Cholangiocarcinoma Pipeline Market Hit Highest Growth Rate In 2031

May 9, 2023 | msn.com

Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know

May 9, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know

May 8, 2023 | finance.yahoo.com

An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 48% Undervalued

May 6, 2023 | americanbankingnews.com

Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Lowered to $34.00 at SVB Securities

May 5, 2023 | finance.yahoo.com

Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

May 5, 2023 | finance.yahoo.com

Q1 2023 Agios Pharmaceuticals Inc Earnings Call

May 4, 2023 | finanznachrichten.de

Agios Pharmaceuticals, Inc.: Agios Reports Business Highlights and First Quarter 2023 Financial Results

May 4, 2023 | seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q1 2023 Earnings Call Transcript

May 4, 2023 | seekingalpha.com

Agios Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation

May 4, 2023 | benzinga.com

Agios Pharmaceuticals: Q1 Earnings Insights

May 4, 2023 | finance.yahoo.com

Agios Reports Business Highlights and First Quarter 2023 Financial Results

May 3, 2023 | marketwatch.com

Dihydrowhey Dehydrogenase (DHODH) Inhibitor Market Size 2023-2031 Industrial Overview by Absolute Reports | with [94 Pages]

May 3, 2023 | americanbankingnews.com

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to Sell

May 2, 2023 | americanbankingnews.com

Agios Pharmaceuticals (AGIO) to Release Quarterly Earnings on Thursday

See More Headlines

AGIO Price History

30 days | 90 days | 365 days | Advanced Chart

AGIO Company Calendar

Last Earnings: 5/04/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AGIO
CUSIP: N/A
CIK: 1439222
Web: www.agios.com
Phone: (617) 649-8600
Fax: N/A
Employees: 390
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.00
High Stock Price Forecast: $41.00
Low Stock Price Forecast: $32.00
Forecasted Upside/Downside: +41.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-231,800,000.00
Net Margins: -1,146.58%
Pretax Margin: -1,146.58%
Return on Equity: -20.23%
Return on Assets: -18.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.55
Quick Ratio: 17.30

Sales & Book Value

Annual Sales: $14.24 million
Price / Sales: 101.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $20.03 per share
Price / Book: 1.30

Miscellaneous

Outstanding Shares: 55,580,000
Free Float: 53,224,000
Market Cap: $1.45 billion
Optionable: Optionable
Beta: 0.94

Key Executives

Brian M. Goff
Chief Executive Officer & Director

Cecilia Jones
Chief Financial Officer

Clive Patience
Chief Technical Operations Officer

Sarah Gheuens
Chief Medical Officer, Head-Research & Development

Charlie Newman
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.
What is Agios Pharmaceuticals' stock price forecast for 2023?: 4 Wall Street research analysts have issued 12-month price targets for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they expect the company's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.
How have AGIO shares performed in 2023?: Agios Pharmaceuticals' stock was trading at $28.08 on January 1st, 2023. Since then, AGIO shares have decreased by 7.2% and is now trading at $26.07.
View the best growth stocks for 2023 here.
When is Agios Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AGIO earnings forecast.
How were Agios Pharmaceuticals' earnings last quarter?: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.25. The biopharmaceutical company earned $5.61 million during the quarter, compared to the consensus estimate of $5.23 million. Agios Pharmaceuticals had a negative trailing twelve-month return on equity of 20.23% and a negative net margin of 1,146.58%. The business's quarterly revenue was up 574.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.74) EPS.
What ETFs hold Agios Pharmaceuticals' stock?: ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS) and WisdomTree U.S. SmallCap Fund (EES).
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?: 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).
What is Agios Pharmaceuticals' stock symbol?: Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."
Who are Agios Pharmaceuticals' major shareholders?: Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.30%), BlackRock Inc. (8.67%), Armistice Capital LLC (6.23%), State Street Corp (5.51%), Farallon Capital Management LLC (3.77%) and Dimensional Fund Advisors LP (3.76%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn.
View institutional ownership trends.
How do I buy shares of Agios Pharmaceuticals?: Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Agios Pharmaceuticals' stock price today?: One share of AGIO stock can currently be purchased for approximately $26.07.
How much money does Agios Pharmaceuticals make?: Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.45 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis.
How many employees does Agios Pharmaceuticals have?: The company employs 390 workers across the globe.
How can I contact Agios Pharmaceuticals?: Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial